Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07868489 in healthy adults and pulmonary arterial hypertension
NCT06137742Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of PF-07868489 in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Started Nov 2023; status: completed.
02
Drugs
PF-07868489
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06137742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137742.